Prostate cancer

The Lancet

Volumn 387, Issue 10013, 2016, Pages 70-82

  Attard, Gerhardt ^a   Parker, Chris ^a   Eeles, Ros A ^a,b   Schröder, Fritz ^c   Tomlins, Scott A ^d   Tannock, Ian ^e   Drake, Charles G ^f   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; BICALUTAMIDE; CABAZITAXEL; CYPROTERONE; DOCETAXEL; ENZALUTAMIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUTAMIDE; MESSENGER RNA; MITOXANTRONE; MYC PROTEIN; NILUTAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CHD1 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA HELICASE; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; SPINK1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CRYOTHERAPY; DIARRHEA; DRUG EFFICACY; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MASS SCREENING; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECTUM HEMORRHAGE; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; URINE INCONTINENCE; WATCHFUL WAITING; BIOPSY; BLOOD; EARLY CANCER DIAGNOSIS; GENETICS; MALE; METABOLISM; PATIENT SELECTION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR SUPPRESSOR GENE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOPSY; CARRIER PROTEINS; DNA HELICASES; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; GENES, BRCA1; GENES, BRCA2; HUMANS; KALLIKREINS; MALE; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-ETS; PTEN PHOSPHOHYDROLASE;

EID: 84954376354     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61947-4     Document Type: Review

References (151)

1. Cancer Research UK Cancer risk http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/risk/ July 27, 2011 (accessed Nov 21, 2012).
2. T Marugame, K Katanoda International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents Vol VIII Jpn J Clin Oncol 36 2006 399 400
3. J Lee, K Demissie, SE Lu, GG Rhoads Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea Cancer Contr 14 2007 78 85
4. T Visakorpi, E Hyytinen, P Koivisto et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 9 1995 401 406
5. CD Chen, DS Welsbie, C Tran et al. Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39
6. ME Taplin, GJ Bubley, TD Shuster et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
7. M Stanbrough, GJ Bubley, K Ross et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res 66 2006 2815 2825
8. JA Locke, ES Guns, AA Lubik et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res 68 2008 6407 6415
9. R Hu, C Lu, EA Mostaghel et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res 72 2012 3457 3462
10. BS Carver, C Chapinski, J Wongvipat et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
11. DE Goldgar, DF Easton, LA Cannon-Albright, MH Skolnick Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands J Natl Cancer Inst 86 1994 1600 1608
12. DJ Schaid The complex genetic epidemiology of prostate cancer Hum Mol Genet 13 suppl 1 2004 R103 R121
13. LE Johns, RS Houlston A systematic review and meta-analysis of familial prostate cancer risk BJU Int 91 2003 789 794
14. K Hemminki, P Vaittinen Familial breast cancer in the family-cancer database Int J Cancer 77 1998 386 391
15. P Lichtenstein, NV Holm, PK Verkasalo et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland N Engl J Med 343 2000 78 85
16. H Grönberg, L Damber, JE Damber Studies of genetic factors in prostate cancer in a twin population J Urol 152 1994 1484 1487
17. CM Zeigler-Johnson, H Rennert, RD Mittal et al. Evaluation of prostate cancer characteristics in four populations worldwide Can J Urol 15 2008 4056 4064
18. BS Carter, TH Beaty, GD Steinberg, B Childs, PC Walsh Mendelian inheritance of familial prostate cancer Proc Natl Acad Sci USA 89 1992 3367 3371
19. RJ MacInnis, AC Antoniou, RA Eeles et al. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies Genet Epidemiol 34 2010 42 50
20. DJ Schaid Transmission disequilibrium, family controls, and great expectations Am J Hum Genet 63 1998 935 941
21. CM Ewing, AM Ray, EM Lange et al. Germline mutations in HOXB13 and prostate-cancer risk N Engl J Med 366 2012 141 149
22. R Eeles, C Goh, E Castro et al. The genetic epidemiology of prostate cancer and its clinical implications Nat Rev Urol 11 2014 18 31
23. ML Freedman, AN Monteiro, SA Gayther et al. Principles for the post-GWAS functional characterization of cancer risk loci Nat Genet 43 2011 513 518
24. N Ahmadiyeh, MM Pomerantz, C Grisanzio et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC Proc Natl Acad Sci USA 107 2010 9742 9746
25. Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers J Natl Cancer Inst 91 1999 1310 1316
26. D Thompson, D Easton the Breast Cancer Linkage Consortium Variation in cancer risks, by mutation position, in BRCA2 mutation carriers Am J Hum Genet 68 2001 410 419
27. Z Kote-Jarai, D Leongamornlert, E Saunders for the UKGPCS Collaborators BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients Br J Cancer 105 2011 1230 1234
28. D Leongamornlert, N Mahmud, M Tymrakiewicz for the UKGPCS Collaborators Germline BRCA1 mutations increase prostate cancer risk Br J Cancer 106 2012 1697 1701
29. C Cybulski, T Huzarski, B Górski et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk Cancer Res 64 2004 2677 2679
30. C Cybulski, D Wokołorczyk, T Huzarski et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer J Med Genet 43 2006 863 866
31. H Erkko, B Xia, J Nikkilä et al. A recurrent mutation in PALB2 in Finnish cancer families Nature 446 2007 316 319
32. SJ Hebbring, H Fredriksson, KA White et al. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer Cancer Epidemiol Biomarkers Prev 15 2006 935 938
33. Z Kote-Jarai, S Jugurnauth, S Mulholland for the UKGPCS Collaborators and the British Association of Urological Surgeons' Section of Oncology A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer Br J Cancer 100 2009 426 430
34. A Mitra, C Fisher, CS Foster for the IMPACT and EMBRACE Collaborators Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype Br J Cancer 98 2008 502 507
35. E Castro, C Goh, D Olmos et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer J Clin Oncol 31 2013 1748 1757
36. H Farmer, N McCabe, CJ Lord et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
37. PC Fong, TA Yap, DS Boss et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval J Clin Oncol 28 2010 2512 2519
38. AJ Vickers, D Ulmert, DD Sjoberg et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study BMJ 346 2013 f2023
39. R Etzioni, R Gulati Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence Med Care 51 2013 304 306
40. EA Heijnsdijk, EM Wever, A Auvinen et al. Quality-of-life effects of prostate-specific antigen screening N Engl J Med 367 2012 595 605
41. FH Schröder, J Hugosson, MJ Roobol for the ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
42. FH Schröder, J Hugosson, MJ Roobol for the ERSPC Investigators Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
43. M Djulbegovic, RJ Beyth, MM Neuberger et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials BMJ 341 2010 c4543
44. D Ilic, MM Neuberger, M Djulbegovic, P Dahm Screening for prostate cancer Cochrane Database Syst Rev 1 2013 CD004720.
45. GL Andriole, ED Crawford, RL Grubb 3rd for the PLCO Project Team Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125 132
46. RL Grubb 3rd, PF Pinsky, RT Greenlee et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial BJU Int 102 2008 1524 1530
47. PF Pinsky, A Blacka, BS Kramer, A Miller, PC Prorok, C Berg Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Clin Trials 7 2010 303 311
48. MJ Roobol, EW Steyerberg, R Kranse et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
49. MJ Bussemakers, A van Bokhoven, GW Verhaegh et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979
50. MJ Roobol, FH Schröder, P van Leeuwen et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
51. T Hambrock, C Hoeks, C Hulsbergen-van de Kaa et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort Eur Urol 61 2012 177 184
52. SC Baca, D Prandi, MS Lawrence et al. Punctuated evolution of prostate cancer genomes Cell 153 2013 666 677
53. C Lin, L Yang, B Tanasa et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer Cell 139 2009 1069 1083
54. R-S Mani, AM Chinnaiyan Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences Nat Rev Genet 11 2010 819 829
55. BS Carver, J Tran, A Gopalan et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nat Genet 41 2009 619 624
56. JC King, J Xu, J Wongvipat et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis Nat Genet 41 2009 524 526
57. CE Barbieri, SC Baca, MS Lawrence et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 2012 685 689
58. MF Berger, MS Lawrence, F Demichelis et al. The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
59. CS Grasso, YM Wu, DR Robinson et al. The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
60. J Lindberg, IG Mills, D Klevebring et al. The mitochondrial and autosomal mutation landscapes of prostate cancer Eur Urol 63 2013 702 708
61. H Beltran, MA Rubin New strategies in prostate cancer: translating genomics into the clinic Clin Cancer Res 19 2013 517 523
62. BS Taylor, N Schultz, H Hieronymus et al. Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
63. SA Tomlins, DR Rhodes, S Perner et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
64. SA Tomlins, B Laxman, SM Dhanasekaran et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer Nature 448 2007 595 599
65. J Clark, G Attard, S Jhavar et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate Oncogene 27 2008 1993 2003
66. MA Rubin, CA Maher, AM Chinnaiyan Common gene rearrangements in prostate cancer J Clin Oncol 29 2011 3659 3668
67. AS Goldstein, J Huang, C Guo, IP Garraway, ON Witte Identification of a cell of origin for human prostate cancer Science 329 2010 568 571
68. T Stoyanova, AR Cooper, JM Drake et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells Proc Natl Acad Sci USA 110 2013 20111 20116
69. X Wang, M Kruithof-de Julio, KD Economides et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer Nature 461 2009 495 500
70. ZA Wang, A Mitrofanova, SK Bergren et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity Nat Cell Biol 15 2013 274 283
71. W Choi, S Porten, S Kim et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 2014 152 165
72. JS Damrauer, KA Hoadley, DD Chism et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology Proc Natl Acad Sci USA 111 2014 3110 3115
73. ST Börno, A Fischer, M Kerick et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation Cancer Discov 2 2012 1024 1035
74. S Huang, ZG Gulzar, K Salari, J Lapointe, JD Brooks, JR Pollack Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness Oncogene 31 2012 4164 4170
75. W Liu, J Lindberg, G Sui et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer Oncogene 31 2012 3939 3948
76. X Mao, Y Yu, LK Boyd et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis Cancer Res 70 2010 5207 5212
77. R Bhalla, LP Kunju, SA Tomlins et al. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma Mod Pathol 26 2013 835 848
78. P Rosen, IA Sesterhenn, SA Brassell, DG McLeod, S Srivastava, A Dobi Clinical potential of the ERG oncoprotein in prostate cancer Nat Rev Urol 2012
79. A Young, N Palanisamy, J Siddiqui et al. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden Am J Clin Pathol 138 2012 685 696
80. JI Epstein, L Egevad, PA Humphrey, R Montironi for the Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference Am J Surg Pathol 38 2014 e6 19
81. J Lindberg, D Klevebring, W Liu et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins Eur Urol 63 2013 347 353
82. L Cheng, SY Song, TG Pretlow et al. Evidence of independent origin of multiple tumors from patients with prostate cancer J Natl Cancer Inst 90 1998 233 237
83. MJ Aryee, W Liu, JC Engelmann et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases Sci Transl Med 5 2013 169ra10
84. W Liu, S Laitinen, S Khan et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer Nat Med 15 2009 559 565
85. A Sboner, F Demichelis, S Calza et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression BMC Med Genomics 3 2010 8
86. G Attard, JF Swennenhuis, D Olmos et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer Cancer Res 69 2009 2912 2918
87. P Mendiratta, E Mostaghel, J Guinney et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer J Clin Oncol 27 2009 2022 2029
88. DT Miyamoto, RJ Lee, SL Stott et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer Cancer Discov 2 2012 995 1003
89. H Beltran, R Yelensky, GM Frampton et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity Eur Urol 63 2013 920 926
90. H Beltran, DS Rickman, K Park et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets Cancer Discov 1 2011 487 495
91. AV Lapuk, C Wu, AW Wyatt et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer J Pathol 227 2012 286 297
92. JM Mosquera, H Beltran, K Park et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer Neoplasia 15 2013 1 10
93. C Parker Active surveillance: towards a new paradigm in the management of early prostate cancer Lancet Oncol 5 2004 101 106
94. L Klotz, L Zhang, A Lam, R Nam, A Mamedov, A Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
95. ED Selvadurai, M Singhera, K Thomas et al. Medium-term outcomes of active surveillance for localised prostate cancer Eur Urol 64 2013 981 987
96. A Bill-Axelson, L Holmberg, M Ruutu for the SPCG-4 Investigators Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364 2011 1708 1717
97. TJ Wilt, MK Brawer, KM Jones for the Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
98. A Widmark, O Klepp, A Solberg for the Scandinavian Prostate Cancer Group Study 7 and the Swedish Association for Urological Oncology 3 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 2009 301 308
99. P Warde, M Mason, K Ding for the NCIC CTG PR.3/MRC UK PR07 investigators Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 2011 2104 2111
100. EM Horwitz, K Bae, GE Hanks et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
101. JW Denham, A Steigler, DS Lamb et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial Lancet Oncol 12 2011 451 459
102. A Bill-Axelson, L Holmberg, H Garmo et al. Radical prostatectomy or watchful waiting in early prostate cancer N Engl J Med 370 2014 932 942
103. S Kumar, M Shelley, C Harrison, B Coles, TJ Wilt, MD Mason Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 4 2006 CD006019.
104. M Bolla, G Van Tienhoven, P Warde et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
105. CU Jones, D Hunt, DG McGowan et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
106. M Bolla, TM de Reijke, G Van Tienhoven for the EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
107. DR Wilke, M Krahn, G Tomlinson, A Bezjak, R Rutledge, P Warde Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy Cancer 116 2010 1909 1917
108. MR Sydes, MKB Parmar, MD Mason et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial Trials 13 2012 168
109. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 355 2000 1491 1498
110. G Gravis, K Fizazi, F Joly et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Lancet Oncol 14 2013 149 158
111. FE Lecouvet, J El Mouedden, L Collette et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62 2012 68 75
112. CJ Ryan, MR Smith, JS de Bono for the COU-AA-302 Investigators Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
113. TM Beer, AJ Armstrong, DE Rathkopf for the PREVAIL Investigators Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
114. IF Tannock, R de Wit, WR Berry for the TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
115. RM Franke, MA Carducci, MA Rudek, SD Baker, A Sparreboom Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer J Clin Oncol 28 2010 4562 4567
116. JS de Bono, S Oudard, M Ozguroglu for the TROPIC Investigators Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
117. L Gan, S Chen, Y Wang et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer Cancer Res 69 2009 8386 8394
118. J Mezynski, C Pezaro, D Bianchini et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947
119. CJ Pezaro, AG Omlin, A Altavilla et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents Eur Urol 66 2014 459 465
120. EJ Small, S Halabi, NA Dawson et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J Clin Oncol 22 2004 1025 1033
121. G Attard, AHM Reid, TA Yap et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
122. G Attard, AHM Reid, R A'Hern et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J Clin Oncol 27 2009 3742 3748
123. CJ Ryan, MR Smith, L Fong et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol 28 2010 1481 1488
124. JS de Bono, CJ Logothetis, A Molina for the COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
125. K Fizazi, HI Scher, A Molina for the COU-AA-301 Investigators Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
126. CJ Logothetis, E Basch, A Molina et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 2012 1210 1217
127. CN Sternberg, A Molina, S North et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy Ann Oncol 24 2013 1017 1025
128. CJ Ryan, MR Smith, K Fizazi et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 2015 152 160
129. J Richards, AC Lim, CW Hay et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 2012 2176 2182
130. C Cai, S Chen, P Ng et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res 71 2011 6503 6513
131. EA Mostaghel, BT Marck, SR Plymate et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin Cancer Res 17 2011 5913 5925
132. C Tran, S Ouk, NJ Clegg et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
133. HI Scher, K Fizazi, F Saad for the AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
134. TM Beer, AJ Armstrong, DE Rathkopf et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
135. MD Balbas, MJ Evans, DJ Hosfield et al. Overcoming mutation-based resistance to antiandrogens with rational drug design eLife 2 2013 e00499
136. VK Arora, E Schenkein, R Murali et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Cell 155 2013 1309 1322
137. KL Noonan, S North, RL Bitting, AJ Armstrong, SL Ellard, KN Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
138. Y Loriot, D Bianchini, E Ileana et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
139. D Bianchini, D Lorente, A Rodriguez-Vida et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone Eur J Cancer 50 2014 78 84
140. ES Antonarakis, C Lu, H Wang et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N Engl J Med 371 2014 1028 1038
141. F Saad, DM Gleason, R Murray the Zoledronic Acid Prostate Cancer Study Group A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
142. K Fizazi, M Carducci, M Smith et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
143. DR Berthold, GR Pond, F Soban, R de Wit, M Eisenberger, IF Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
144. PW Kantoff, CS Higano, ND Shore for the IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
145. C Parker, S Nilsson, D Heinrich the ALSYMPCA Investigators Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
146. B Kearns, M Lloyd Jones, M Stevenson, C Littlewood Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal Pharmacoeconomics 31 2013 479 488
147. M Dyer, F Rinaldi, E George, AI Adler NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen Lancet Oncol 13 2012 762 763
148. K McKeage, GL Plosker Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases Pharmacoeconomics 26 2008 251 268
149. SJ Snedecor, JA Carter, S Kaura, MF Botteman Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis J Med Econ 16 2013 19 29
150. ML Huber, L Haynes, C Parker, P Iversen Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer J Natl Cancer Inst 104 2012 273 279
151. PW Kantoff, TJ Schuetz, BA Blumenstein et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105